CENTER FOR INQUIRY, INC. OFFICE OF PUBLIC POLICY

CFI's Office of Public Policy lobbied against S. 4692, the "Homeopathic Drug Product Safety, Quality, and Transparency Act." This legislation would allow lax federal regulation of the homeopathy industry, using homeopathy-specific standards set by the industry for safety and efficacy. While homeopathy groups favor this approach, evidence shows that these products are not safe for American consumers and patients. The Office of Public Policy continues to raise awareness among Congressional offices regarding this public health issue.